Providing patients with comprehensive ... and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management ... Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. It was tested in the VALOR study, the largest placebo-controlled dermatomyositis trial ever conducted. In VALOR, patients taking LISRAYA saw clinically meaningful improvement across a broad range of disease measures, including global myositis response, cutaneous disease, muscle strength, functional disability and steroid sparing. "We're excited to partner with Orsini in offering this potentially transformative therapy for the dermatomyositis community," Daniel Herz-Roiphe, Chief Operating Officer at Priovant, said. ELK GROVE VILLAGE, Ill., Aug. 28, 2026 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, announced today that it is a specialty pharmacy partner for Priovant's LISRAYA™ (brepocitinib), a once-daily oral therapy for the treatment of adults with dermatomyositis. "This approval represents new hope for a population whose treatment options were previously very limited, and Orsini's deep experience in rare disease therapies will ensure that patients have a seamless experience as they gain access to LISRAYA."

Original title: “Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib) - BioSpace”

The drug boasts a broad label, ... level of disease activity, clinical presentation or previous treatment, Priovant said. The drug can be used as both an alternative therapy or an add-on to current non-targeted DM medicines, the company explained. ... The approval was propped up by data from Priovant’s late-stage Valor trial, which the ... The drug boasts a broad label, too, cleared for use in adult DM patients without restriction based on level of disease activity, clinical presentation or previous treatment, Priovant said. The drug can be used as both an alternative therapy or an add-on to current non-targeted DM medicines, the company explained. ... The approval was propped up by data from Priovant’s late-stage Valor trial, which the company touts as the biggest DM study ever conducted. Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing its first approval in a rare skin disease. | Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing its first approval in a rare skin disease. While the company had settled on dermatomyositis as the drug’s lead indication in the pivot into phase 3, a phase 2 lupus trial flop in 2023 put a blemish on the drug’s clinical track record. Priovant is eventually hoping to score additional indications for the molecule, which is also in phase 3 testing in noninfectious uveitis and recently began enrolling patients in a late-stage study in cutaneous sarcoidosis. Roivant Pfizer autoimmune disease rare diseases U.S. In its approval announcement, Priovant noted that improvements to TIS in patients on Lisraya came as early as four weeks, increased over time and were sustained through the end of the trial period. Additionally, 55% of patients treated with Lisraya were able to achieve both moderate or better improvement on the TIS alongside minimal or no steroid use by the study’s end, as compared to 30% of patients in the control arm. In attempting to frame Lisraya’s potential merit in the DM community, Priovant highlighted patients’ own impression of their experience, noting that when asked about the overall activity of their disease, patients on Lisraya reported more than four times as much improvement as those who got the dummy drug.

Original title: “Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease | Fierce Pharma”

fulminant anti nuclear matrix protein 2 antibody positive dermatomyositis with massive anasarca bulbar involvement and respiratory failure recovery after prolonged immunosuppression and rehabilitation

Original title: “Fulminant anti-nuclear matrix protein 2 antibody-positive dermatomyositis with massive anasarca, bulbar involvement and respiratory failure: recovery after prolonged immunosuppression and rehabilitation.”

aqp4 nmosd mda5 clinically amyopathic dermatomyositis and shlh in a pediatric patient a case report and literature review

Original title: “AQP4+ NMOSD, MDA5+ Clinically Amyopathic Dermatomyositis and sHLH in a Pediatric Patient: A Case Report and Literature Review.”

peripheral eosinophilia in amyopathic dermatomyositis an atypical presentation with diagnostic and therapeutic implications

Original title: “Peripheral eosinophilia in amyopathic dermatomyositis: an atypical presentation with diagnostic and therapeutic implications.”

clinical characteristics and long term prognosis of anti mda5 positive dermatomyositis a comparative study across age groups

Original title: “Clinical characteristics and long-term prognosis of anti-MDA5-positive dermatomyositis: a comparative study across age groups.”

dermatomyositis masquerading as angioedema a crucial differential not to overlook

Original title: “Dermatomyositis masquerading as angioedema: a crucial differential not to overlook.”

anti mda5 antibody positive dermatomyositis in emirati patients a case series highlighting clinical variability

Original title: “Anti-MDA5 Antibody-Positive Dermatomyositis in Emirati Patients: A Case Series Highlighting Clinical Variability.”

anti sae antibody positive dermatomyositis presenting with widespread erythema complicated by rosai dorfman disease

Original title: “Anti-SAE Antibody-Positive Dermatomyositis Presenting With Widespread Erythema Complicated by Rosai-Dorfman Disease.”

Conditions: IBM; IIM; Myositis; Inflammatory Myopathy; Dermatomyositis; Dermatomyositis, Juvenile; Anti-synthetase Syndrome; Immune-Mediated Necrotizing Myopathy; Polymyositis; Inclusion Body Myositis; Juvenile Myositis; Juvenile Dermatomyositis Interventions: Other: No intervention - qualitative and mixed methods investigations Sponsors: Myositis International Health & Research Collaborative Alliance Foundation; MIHRA Patient Advisory; Myositis Australia; CureJM; The Myositis Association; The D

Original title: “MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)”